Lilly’s offering is expected to surpass Novo’s Wegovy in the space, and, according to a report this week from GlobalData, it ...

The emergence of adaptive cardiac devices, especially those that utilise AI, is propelling the wider industry shift towards ...

The surge in tunnelling and anchoring machinery patents is driven by the need for technological innovation to improve mining processes.

Operational risks are also reduced due to a lesser need for human intervention in hazardous environments, which is a very ...

It’s become evident that a cloud-based IT portfolio brings organisations the greatest promise for providing the type of ...

The growing adoption of smart home technology is enabling consumers to both spot damage early and reduce its impact by ...

KOLs interviewed by GlobalData stressed the lack of biologic therapies specifically targeting T2-low asthma.

In a release sent to Rigzone recently, GlobalData said the oil and gas industry has seen a dip in active jobs in 2024 but ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound will overtake competitors.

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

Prasanth Katam, an insurance analyst at GlobalData, noted that South Korea’s economy grew by only 1.4% in 2023, which ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.